Strategies to Reduce Acute Kidney Injury in Angioplasty

The title of this article leads us to think that we will find a list of things that we can do to reduce kidney injury. However, (unfortunately) sodium bicarbonate showed no benefit over saline and n-acetylcysteine showed no benefit over a placebo for the reduction of kidney damage after coronary angioplasty.

Sub análisis del EXCEL: angioplastia vs cirugía en insuficiencia renal crónicaAmong the protective measures most frequently tested are endovenous sodium bicarbonate and oral n-acetylcysteine, both with conflicting results.

 

The PRESERVE (Prevention of Serious Adverse Events Following Angiography) trial used a 2 × 2 factorial design and randomized 5177 patients with stage III or IV renal insufficiency requiring angiography to 1.26% sodium bicarbonate or 0.9% sodium chloride and n-acetylcysteine or placebo for 5 days. The primary endpoint was a composite of death, need for dialysis, or persistent renal insufficiency at 90 days. Contrast-associated acute kidney injury was a secondary endpoint.


Read also: Contrast Induced Kidney Injury, Infamous Problem with No Magical Solutions.


A total of 1161 study patients underwent coronary angioplasty. The mean glomerular filtration rate was 50.7 mL/min/1.73 m2 and 82% of the population had a history of diabetes.

 

The primary endpoint occurred in 2.6% of patients who received sodium bicarbonate vs. 4% of patients who received saline (p = 0.41) and in 3.8% of patients who received n-acetylcysteine vs. 2.8% of patients who received a placebo (p = 0.29). There were no significant differences among groups as regards the incidence of contrast-associated kidney injury.

 

Conclusion

Among patients with chronic kidney disease who underwent angioplasty, there was no benefit of sodium bicarbonate over regular saline or of n-acetylcysteine over placebo for the prevention of contrast-associated kidney injury.

 

Original title: Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes Following Percutaneous Coronary Intervention. A Subgroup Analysis of the PRESERVE Trial.

Reference: Santiago Garcia et al. J Am Coll Cardiol Intv 2018;11:2254-61.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...